Lack of ROS1 gene rearrangement in glioblastoma multiforme

Sun Min Lim, Junjeong Choi, Jong Hee Chang, Jinyoung Sohn, Kristine Jacobson, Frank Policht, John Schulz, Byoung Chul Cho, Se Hoon Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2%) cases, and IDH1 mutation was found in 6 (5.5%) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.

Original languageEnglish
Article numbere0137678
JournalPloS one
Volume10
Issue number9
DOIs
Publication statusPublished - 2015 Sep 14

Fingerprint

Gene Rearrangement
Glioblastoma
Isocitrate Dehydrogenase
Methylation
Genes
Methyltransferases
isocitrate dehydrogenase
Assays
methyltransferases
fluorescence in situ hybridization
methylation
Tissue
immunohistochemistry
genes
DNA
Biomarkers
Ports and harbors
Fluorescence In Situ Hybridization
mutation
Paraffin

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Lim, S. M., Choi, J., Chang, J. H., Sohn, J., Jacobson, K., Policht, F., ... Kim, S. H. (2015). Lack of ROS1 gene rearrangement in glioblastoma multiforme. PloS one, 10(9), [e0137678]. https://doi.org/10.1371/journal.pone.0137678
Lim, Sun Min ; Choi, Junjeong ; Chang, Jong Hee ; Sohn, Jinyoung ; Jacobson, Kristine ; Policht, Frank ; Schulz, John ; Cho, Byoung Chul ; Kim, Se Hoon. / Lack of ROS1 gene rearrangement in glioblastoma multiforme. In: PloS one. 2015 ; Vol. 10, No. 9.
@article{ffd80317a7ed4a6c938f32721f95a098,
title = "Lack of ROS1 gene rearrangement in glioblastoma multiforme",
abstract = "Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2{\%}) cases, and IDH1 mutation was found in 6 (5.5{\%}) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.",
author = "Lim, {Sun Min} and Junjeong Choi and Chang, {Jong Hee} and Jinyoung Sohn and Kristine Jacobson and Frank Policht and John Schulz and Cho, {Byoung Chul} and Kim, {Se Hoon}",
year = "2015",
month = "9",
day = "14",
doi = "10.1371/journal.pone.0137678",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

Lim, SM, Choi, J, Chang, JH, Sohn, J, Jacobson, K, Policht, F, Schulz, J, Cho, BC & Kim, SH 2015, 'Lack of ROS1 gene rearrangement in glioblastoma multiforme', PloS one, vol. 10, no. 9, e0137678. https://doi.org/10.1371/journal.pone.0137678

Lack of ROS1 gene rearrangement in glioblastoma multiforme. / Lim, Sun Min; Choi, Junjeong; Chang, Jong Hee; Sohn, Jinyoung; Jacobson, Kristine; Policht, Frank; Schulz, John; Cho, Byoung Chul; Kim, Se Hoon.

In: PloS one, Vol. 10, No. 9, e0137678, 14.09.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lack of ROS1 gene rearrangement in glioblastoma multiforme

AU - Lim, Sun Min

AU - Choi, Junjeong

AU - Chang, Jong Hee

AU - Sohn, Jinyoung

AU - Jacobson, Kristine

AU - Policht, Frank

AU - Schulz, John

AU - Cho, Byoung Chul

AU - Kim, Se Hoon

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2%) cases, and IDH1 mutation was found in 6 (5.5%) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.

AB - Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2%) cases, and IDH1 mutation was found in 6 (5.5%) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.

UR - http://www.scopus.com/inward/record.url?scp=84947447625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947447625&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0137678

DO - 10.1371/journal.pone.0137678

M3 - Article

C2 - 26366867

AN - SCOPUS:84947447625

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0137678

ER -

Lim SM, Choi J, Chang JH, Sohn J, Jacobson K, Policht F et al. Lack of ROS1 gene rearrangement in glioblastoma multiforme. PloS one. 2015 Sep 14;10(9). e0137678. https://doi.org/10.1371/journal.pone.0137678